Uveal melanoma guidelines

Uveal melanoma is a very rare form of the disease, which is managed differently from other melanomas. Comprehensive guidance on this subject was developed for the first time in 2015. This guideline was developed by a leading clinical and research specialist interdisciplinary group with patient input. While much of the guideline is still current, the 2022 guidelines updated the following sections:

  • molecular pathology and features
  • prognostic markers
  • loco-regional management of hepatic predominant disease
  • management of metastatic disease
  • adjuvant radiation therapy
  • support of patients

Uveal melanoma is a very rare form of the disease, it requires different clinical management from other melanomas

According to NICE methodology the areas updated in the 2022 guidelines were selected where there was a significant update in the evidence base. Surveillance was not included within this update.  It was, however, recognised that the UK medical and patient community would benefit from further guidance on post treatment metastatic surveillance of uveal melanoma and therefore an additional Guidelines Development Group chaired by Dr Matthew Wheater was set up to enhance the current guidance and pathway. The guidance was therefore further updated in 2023.

Uveal Melanoma Guidelines

We are extremely grateful to Professor Paul Nathan, Trustee (Consultant Medical Oncologist, Mount Vernon Cancer Centre) for chairing the Guidelines Development Group (GDG) which formed in 2020 to review the 2015 guidelines and to Dr Matthew Wheater (Consultant Medical Oncologist, University Hospital Southampton) for chairing the 2022 surveillance GDG. The groups are from fields of medical oncology, clinical oncology, radiology, pathology, uveal melanoma science and patient representation with project management and methodological support provided by Mrs Nancy Turnbull, the Project Manager.

Follow the individual links below for the relevant guidelines:

uveal diagram

Following the completion of the Uveal melanoma guidelines, Professor Paul Nathan stated:

“The Uveal Melanoma National Guidelines have recommended standards of care for all of our patients across the UK. These updated guidelines include recent advances in our understanding of the distinct biology of this disease, assess the evidence for recent improvements in care and have a renewed focus on patient experience. We believe they will continue to be an important reference document for patients, their supporters and clinicians.  I would like to particularly thank Nancy Turnbull for facilitating the process and my colleagues on the guidelines committee who have given so much of their time and expertise to this worthwhile effort. Furthermore, these updated guidelines wouldn’t have materialised without the funding from Melanoma Focus who received a welcome donation from OcuMelUK”.

 

Dr Matthew Wheater chair of the Surveillance Guidelines Development Group said:

“I’m really pleased to see the guidelines finalised with the addition of post treatment and metastatic surveillance for uveal melanoma included.  The Guideline Development Group have been excellent in comprehensively reviewing the evidence and producing guidelines which I hope will give confidence to patients and clinicians about optimal evidence based care”.

Essential Ocular Oncology: A Guide for Practitioners

Professor Bertil Damato has provided password protected access to Essential Ocular Oncology: A Guide for Practitioners.

This has been password protected as the pictures of patients used in this guideline were collected over the past 22 years and during this time a proportion of the patients have died, this has meant that the authors of the guide have been unable to obtain consent to show the patients pictures in the public domain. Therefore, this guide can only be used for professional teaching purposes.

Click here to access the password protected document.

Research invitation: Development of a quality of life questionnaire for people with metastatic uveal melanoma

Medical oncologist Prof Anthony Joshua and collaborators at the University of Technology Sydney (UTS) are conducting a study to develop a questionnaire for measuring impacts on quality of life from metastatic uveal melanoma and its treatment for use in future clinical trials.

Participation will involve a 30-minute interview or focus group in which you will be asked about the impacts on quality of life you have observed from metastatic uveal melanoma and its treatment.

Clinicians from all disciplines – medical, nursing and allied health – are invited to participate.

Interviews/Focus groups can be conducted either face to face or via Zoom.

If you would like further information, please contact the co-ordinating investigator, Dr Tim Luckett, via tim.luckett@uts.edu.au

This study has been approved by the St Vincent’s Hospital Human Research Ethics

CURE OM Patient VISION Registry

This international registry is funded and sponsored by the Melanoma Research Foundation’s CURE  OM initiative. The patient-reported ocular melanoma registry is an online database that securely collects, stores, monitors, analyses and shares data for research purposes. Open to patients and caregivers, registration is required and several personalised surveys to document diagnosis and treatment are requested. Participants can save their progress and continue the surveys at a future time and can revisit their records to update any changes.

Please share this link with your patients: https://melanoma.org/visionregistry/

COPYRIGHT NOTICE: ALL documents are Copyright © 2018 & 2020, 2023 Melanoma Focus. Permission is granted to reproduce them, with attribution to Melanoma Focus, for personal clinical and educational use only. Commercial copying or lending is prohibited.

Further resources

Nathan P, et al. Uveal Melanoma Guideline Development Working Group. Uveal Melanoma UK National Guidelines. Eur J Cancer. 2015 Nov;51(16):2404-12. doi: 10.1016/j.ejca.2015.07.013. Epub 2015 Aug 13. PMID: 26278648.
The full text PDF publication is available to download here

NB: These Guidelines were developed in accordance with the Melanoma Focus Guideline Development Methodology Manual. The methods have been accredited by NICE as complying with their AGREE II criteria for the rigorous development of evidence-based guidelines.
Nice accredited logo